Brighter strengthens its financing with 0,9 MSEK through exercise of warrants.
The second exercise period for Brighter’s warrants of series TO3 is now completed. The company thereby strengthens its financing with 884 444 SEK, representing 221,111 new shares.
The subsequent four exercise periods are:
11 - 25 October 2018
11 - 25 April 2019
11 - 25 October 2019
10 - 24 April 2020
Those who subscribed in this exercise period have now obtained Interim Shares. Once the registration has been completed with the Swedish Companies Registration Office, conversion of the interim shares will automatically take place without further notice to the holders. The conversion is expected to occur within approximately one week from the completed registration. The interim shares will not be listed for trading.
Through this warrant exercise the number of shares and votes in Brighter will increase by 221,111 to a total of 66,978,124.
For terms and conditions of the Warrants, please visit: http://brighter.se/en/investors/documents/.
For more information, please contact:
Truls Sjöstedt, CEO
Tel: +46 709 73 46 00
Email: truls.sjostedt@brighter.se
Ann Zetterberg, CFO
Tel: +46 708 37 21 23
Email: ann.zetterberg@brighter.se
About Brighter
Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of healthcare’s biggest challenges: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing, and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop™ - is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and their close associates, healthcare providers, research institutes, the pharmaceutical industry, and society as a whole. www.brighter.se
About Actiste
Brighter's solution Actiste® handles most of the self-monitoring and treatment of insulin-treated diabetes in a single easy-to-use device. Measurement of glucose levels, insulin injections, automatic logging, and timing of all activities are performed from a single unit. Actiste is connected via an autonomous and secure mobile connection, and information can be automatically shared with selected recipients through The Benefit Loop®, Brighter's open cloud-based service where data is collected, processed and analyzed with patient consent.
Validated user-generated data, such as glucose levels or insulin doses, can be automatically transferred electronically to many different constituents. The patient selects when and how data is shared and who will have access to it. Through The Benefit Loop, different services can motivate patients with chronic illnesses to change their behavior, which can save lives, reduce relatives' concerns, and release enormous healthcare resources. www.actiste.com
The Company's shares are listed on NASDAQOMX First North/BRIG. Brighter’s Certified Adviser on Nasdaq OMX First North is Remium Nordic Holding AB +46 (0)8 – 454 32 50, CorporateFinance@remium.com, www.remium.com.
This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 12:00 CEST on May 9, 2018.